New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in Resected High-Risk Melanoma Patients Presented at ASCO

close

Get every new post delivered right to your inbox.

Original Source